Eudra GMP - Public Layout

MIA | GMP | API REG | WDA | GDP | Sites

Help

Wed 11 Nov 2026 18:16:56 BST

GMP Compliance Menu

GMP Certificates

Non-Compliance Report

Print Preview

Print Preview (Short version)

Back To Search

Regierung Von Oberfranken

CERTIFICATE NUMBER: DE_BY_05_GMP_2024_0059

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1) , (2)

Part 1

Issued following an inspection in accordance with
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Germany confirms the following:

The manufacturer: Qilu Antibiotics Pharmaceutical Co. Ltd.

Site address:

No. 849 Dongjia Town, Licheng District, Jinan, 250105, China

OMS Organisation Id. / OMS Location Id.: ORG-100033695 / LOC-100052910

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art. 19(3) of Regulation 726/2004/EC.

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC1 transposed in the following national legislation:Sect. 64 para 1 and 3 German Medicinal Product Act.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2024-05-31 , it is considered that it complies with:

The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572. (3)

The principles of GMP for active substances referred to in Article 47 of Directive 2001/83/EC and an appropriate level of GMP as referred to in Article 46(f) of Directive 2001/83/EC transposed in the following national legislation:Sect. 64 para 1 and 3 German Medicinal Product Act.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or clarifying remarks can be identified through the EudraGMDP website (https://eudragmdp.ema.europa.eu/). This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

__________________________________________________________________________________________________________________________

(1) The certificate referred to in paragraph Art. 111(5) of Directive 2001/83/ECis also applicable to importers.
(2) Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate.
(3) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products

1 MANUFACTURING OPERATIONS

1.1 Sterile products

   1.1.1  Aseptically prepared (processing operations for the following dosage forms)
           1.1.1.5  Solids and implants
   1.1.3  Batch certification

1.4 Other products or manufacturing activity

   1.4.2  Sterilisation of active substance/ excipients/ finished product
           1.4.2.1  Filtration
   1.4.3  Other
             Special Requirements:
                1  B-lactam Antibiotics

1.5 Packaging

   1.5.1  Primary Packaging
           1.5.1.8  Other solid dosage forms
                  Special Requirements:
                   1  B-lactam Antibiotics

1.6 Quality control testing

   1.6.1  Microbiological: sterility
   1.6.3  Chemical/Physical
   1.6.4  Biological

Manufacture of active substance. Names of substances subject to inspection:

[00022084-00001]Ceftazidime hydrochloride; Cefepime hydrochloride(en)

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance:Ceftazidime hydrochloride; Cefepime hydrochloride

3.1 Manufacture of Active Substance by Chemical Synthesis

3.1.1  Manufacture of active substance intermediates

3.1.2  Manufacture of crude active substance

3.1.3  Salt formation / Purification steps:
Ceftazidime hydrochloride; Cefepime hydrochloride

3.4 Manufacture of sterile Active Substance

3.4.1  Aseptically prepared

3.5 General Finishing Steps

3.5.2  Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)

3.6 Quality Control Testing

3.6.1  Physical / Chemical testing

3.6.3  Microbiological testing including sterility testing

3.6.4  Biological Testing

Clarifying remarks (for public users):

to 1.1.1.5 and 1.1.3: Production an Release of sterile bulk medicinal products (powder in tins) to 1.4.2.1 and 1.5.1.8: related to 1.1.1.5 Inspected sterile medicinal bulk products: - Ceftazidime Pentahydrate; - Sodium Carbonate; - Ceftazidime Pentahydrate with sodium carbonate for injection; - Cefepime Dihydrochloride Monohydrate; - L-Arginine; - Cefepime Dihydrochloride Monohydrate with L-Arginine for injection Inspected buildings: a) Workshop 720 - Unit 722: Production of unsterile API Ceftazidime b) Workshop 800 - Unit 802: Production of unsterile API Cefepime c) Workshop 500 - Unit 500: Production of sterile bulk medicinal products Ceftazidime Pentahydrate; Sodium carbonate; Ceftazidime Pentahydrate with sodium carbonate for injection, Cefepime Dihydrochloride Monohydrate; L-Arginine; Cefepime Dihydrochloride Monohydrate with L-Arginine

The EudraGMDP database is maintained and operated by the EMA. Access to the general public is granted in order to enhance availability of information related to the EMA mandate. The content of the database is provided by the National Competent Authorities (NCA) of the EEA. For this reason, the EMA accepts no responsibility or liability whatsoever (including but not limited to any direct or consequential loss or damage it might occur to you and/or any other third party) arising out of or in connection with the information on this database. Any questions about the content should be addressed to the relevant NCA. Please click here to get list of NCA's.

For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI.

Documents issued by UK authorities up to and including 31 December 2020 remain available for consultation in EudraGMDP. However, they are no longer included or updated from 1 January 2021, with the exception of the documents pertaining to sites located in Northern Ireland.